DE68916777T2 - Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis. - Google Patents

Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis.

Info

Publication number
DE68916777T2
DE68916777T2 DE68916777T DE68916777T DE68916777T2 DE 68916777 T2 DE68916777 T2 DE 68916777T2 DE 68916777 T DE68916777 T DE 68916777T DE 68916777 T DE68916777 T DE 68916777T DE 68916777 T2 DE68916777 T2 DE 68916777T2
Authority
DE
Germany
Prior art keywords
psoriasis
tnf
necrosis factor
tumor necrosis
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68916777T
Other languages
German (de)
English (en)
Other versions
DE68916777D1 (de
Inventor
Patrick Joseph Creaven
Kazuyoshi Hori
Hiroshi Ishimaru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Chemical Industry Co Ltd
Original Assignee
Asahi Chemical Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Chemical Industry Co Ltd filed Critical Asahi Chemical Industry Co Ltd
Application granted granted Critical
Publication of DE68916777D1 publication Critical patent/DE68916777D1/de
Publication of DE68916777T2 publication Critical patent/DE68916777T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DE68916777T 1988-12-27 1989-12-04 Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis. Expired - Lifetime DE68916777T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29049788A 1988-12-27 1988-12-27

Publications (2)

Publication Number Publication Date
DE68916777D1 DE68916777D1 (de) 1994-08-18
DE68916777T2 true DE68916777T2 (de) 1995-03-16

Family

ID=23116275

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68916777T Expired - Lifetime DE68916777T2 (de) 1988-12-27 1989-12-04 Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis.

Country Status (7)

Country Link
EP (1) EP0377823B1 (enExample)
JP (1) JPH02209812A (enExample)
AT (1) ATE108331T1 (enExample)
AU (1) AU633037B2 (enExample)
CA (1) CA2003981C (enExample)
DE (1) DE68916777T2 (enExample)
DK (1) DK658889A (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2659235A1 (fr) * 1990-03-09 1991-09-13 Asahi Chemical Ind Application du facteur tumoral de necrose au traitement des troubles de demyelinisation, de l'uveite ou des troubles de l'hote qui a recu une greffe.
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US8715664B2 (en) 2005-05-16 2014-05-06 Abbvie Biotechnology Ltd. Use of human TNFα antibodies for treatment of erosive polyarthritis
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
CN106729633A (zh) * 2017-03-03 2017-05-31 上海唯科生物制药有限公司 一种肿瘤坏死因子直肠给药制剂及其制备方法
US20240108746A1 (en) * 2020-12-16 2024-04-04 Molecular Partners Ag Novel slow-release prodrugs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
AU2844889A (en) * 1988-01-22 1989-07-27 Collagen Corporation Method for suppressing the growth of normal and cancer cells

Also Published As

Publication number Publication date
EP0377823A3 (en) 1991-09-11
EP0377823B1 (en) 1994-07-13
EP0377823A2 (en) 1990-07-18
ATE108331T1 (de) 1994-07-15
AU633037B2 (en) 1993-01-21
CA2003981A1 (en) 1990-06-27
AU4685389A (en) 1990-07-05
JPH0565492B2 (enExample) 1993-09-17
CA2003981C (en) 2000-06-13
JPH02209812A (ja) 1990-08-21
DE68916777D1 (de) 1994-08-18
DK658889D0 (da) 1989-12-22
DK658889A (da) 1990-06-28

Similar Documents

Publication Publication Date Title
US5342613A (en) Pharmaceutical compositions and use thereof in the treatment of psoriasis
DE69434121T2 (de) Pharmazeutische zusammensetzung zur immunverstärkenden therapie
DE69010162T2 (de) Zusammensetzung zur Behandlung von Entzündung.
JPS63502985A (ja) 角膜基質創傷の治療のための組成物
DE69431300T2 (de) Eine pharmazeutische oder kosmetische zubereitung, die eine kolostrumfraktion enthält und deren medizinische verwendung
EP1133992B1 (en) Novel pharmacological activities of curcuma longa extracts
EP2563370B1 (de) Verwendung einer phospholipid und glycyrrhizinsäure enthaltenden zusammensetzung zur entfernung von subkutanen fettansammlungen durch subkutane lipolyse
DE69024053T2 (de) Behandlung zur ermässigung von ödem und muskelschäden.
DE3853721T2 (de) Verwendungen von rekombinantem koloniestimulierendem faktor-1.
DE68909100T2 (de) Physiologisch wirkende Substanzen, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen davon.
US5028422A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
DE68916777T2 (de) Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis.
DE69232596T2 (de) Inhibitor von nebenwirkungen zur krebstherapy
EP0231819A2 (en) Pharmaceutical agent for the treatment of myelogenous leukemia
Aly et al. Topical griseofulvin in the treatment of dermatophytoses
EP0305181B1 (en) Ethyl-(+)-apovincaminate for treating demyelinization clinical patterns of autoimmune origin
DE3876817T2 (de) Anwendung des humanblut-koagulationsfaktors-xiii zur behandlung von colitis gravis.
DE3750464T2 (de) Pharmazeutisches Präparat zur Behandlung des Katarakts.
DE69804466T2 (de) Robinia pseudoacacia lektin und seine verwendungen
US5514652A (en) Therapy of respiratory tract diseases using basic fibroblast growth factor
JP3631245B2 (ja) ＤＮＡウイルス感染の治療のための薬物の製造のための膜翅類昆虫（ｈｙｍｅｎｏｐｔｅｒａ）毒の使用
DE102011003478A1 (de) Antivirales Mittel enthaltend rekombinante Mistellektine
EP0885013B1 (de) Verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren zur herstellung von arzneimitteln
JP2681467B2 (ja) ヒト白血球インターフエロン含有局所用組成物
DE3788899T2 (de) Intraläsionale Behandlung von Basalzellenkarzinoma mittels rekombinanten humanen alpha-Interferons.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8330 Complete renunciation